Brief: Amneal Resubmits DHE Autoinjector New Drug Application And Receives U.S. FDA Approval Of Exenatide
21/11/2024 21:07
Nov 21 (Reuters) - Amneal Pharmaceuticals Inc AMRX.O :
* AMNEAL RESUBMITS DHE AUTOINJECTOR NEW DRUG APPLICATION AND
RECEIVES U.S. FDA APPROVAL OF EXENATIDE, ITS FIRST GENERIC
INJECTABLE GLP-1 AGONIST
* AMNEAL PHARMACEUTICALS INC - FDA REVIEW OF DHE
AUTOINJECTOR NDA
EXPECTED BY Q2 2025
Source text: ID:nBw6sd0Zta
Further company coverage: AMRX.O
Recent news on Amneal Pharmaceuticals
See all newsFocus: US progesterone supplies tighten as menopause treatment demand grows
U.S. STOCKS ON THE MOVE-Chipotle Mexican Grill, J.B. Hunt, ABM Industries
U.S. STOCKS ON THE MOVE-G-III Apparel, Amneal Pharmaceuticals, BioCardia
U.S. STOCKS ON THE MOVE-Lululemon, Cooper Companies, Cypherpunk Technologies
Amneal Pharma up after Parkinson’s drug shows benefit in late-stage study